Sponsored Links
| Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia |
 |
 |
 |
| Medical News - Hematology | |||
|
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S... Read more: Blood / Hematology News From Medical News Today
|